RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer

Modern Pathology

Volumn 26, Issue 8, 2013, Pages 1111-1122

  Guerrero Setas, David ^a   Pérez Janices, Noemí ^a   Blanco Fernandez, Laura ^a   Ojer, Amaya ^a   Cambra, Koldo ^a   Berdasco, María ^b   Esteller, Manel ^b   Maria Ruiz, Sergio ^a   Torrea, Natalia ^a   Guarch, Rosa ^c  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c Universidad Pública de Navarra   (Spain)

Author keywords

5 aza 2 deoxycytidine; Cervical cancer; DNA methylation; EPB41L3; Prognosis; RASSF1; RASSF2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; EPB41L3 PROTEIN; MESSENGER RNA; ONCOPROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RASSF2 PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENOTYPE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SQUAMOUS CERVICAL CARCINOMA; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICROFILAMENT PROTEINS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84881310411     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.32     Document Type: Article

References (46)

1. Stat bite: Cervical cancer mortality worldwide. J Natl Cancer Inst 2006;98:434.
2. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88: 63-73.
3. Wells M, Ostor AG, Crum CP, et al. Tumours of the uterine cervix: Epithelial tumours, in World Health Organization Classification of Tumours, In: Tavassoli FA, Devilee P(eds). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. The International Agency for Research on Cancer Press: Lyon, France; 2003, pp 259-289.
4. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 2010;102: 1478-1488.
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
6. Cooper WN, Hesson LB, Matallanas D, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009;28:2988-2998.
7. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009;1796:114-128.
8. Vos MD, Ellis CA, Elam C, et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003;278:28045-28051.
9. Maruyama R, Akino K, Toyota M, et al. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 2008;29:1312-1318.
10. Cooper WN, Dickinson RE, Dallol A, et al. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 2008;27:1805-1811.
11. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005;24:3987-3994.
12. Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 2008;123:296-302.
13. Schagdarsurengin U, Richter AM, Hornung J, et al. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010;9:p 264.
14. Vos MD, Ellis CA, Elam C, et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000;275:35669-35672.
15. Mitra S, Mazumder Indra D, Basu PS, et al. Alterations of RASSF1A in premalignant cervical lesions: Clinical and prognostic significance. Mol Carcinogen 2012;51:723-733.
16. Huang KH, Huang SF, Chen IH, et al. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res 2009;15:4174-4180.
17. Eijsink JJ, Lendvai A, Deregowski V, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012;130:1861-1869.
18. Heller G, Geradts J, Ziegler B, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007;103: 283-291.
19. Yamada KS, Sakurai-Yageta WY, Masuda M, et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 2006;118:916-923.
20. Kikuchi S, Yamada D, Fukami T, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 2005;11:2954-2961.
21. Haie-Meder C, Maurice P, Castiglione M. ESMO Guidelines Working Group. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:37-40.
22. Nonogaki S, Wakamatsu A, Filho AL, et al. Molecular strategies for identifying human papillomavirus infection in routinely processed samples: Focus on paraffin sections. J Low Genit Tract Dis 2005;9: 219-224.
23. Van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-787.
24. Herman JG, Graff JR, Myohanen S, et al. Methylationspecific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821-9826.
25. Guerrero D, Guarch R, Ojer A, et al. Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU International 2008;102:747-755.
26. Luo D, Ye T, Li TQ, et al. Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med 2012;3:391-396.
27. de Kok IM, van der Aa MA, van Ballegooijen M, et al. Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached? Int J Cancer 2010;128:2174-2181.
28. Henken FE, Wilting SM, Overmeer RM, et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007;97: 1457-1464.
29. Katargin AN, Pavlova LS, Kisseljov FL, et al. Hypermethylation of genomic 3.3-kb repeats is frequent event in HPV-positive cervical cancer. BMC Med Genom 2009;2:30.
30. de Wilde J, Kooter JM, Overmeer RM, et al. hTERT promoter activity and CpG methylation in HPVinduced carcinogenesis. BMC Cancer 2010;10:271.
31. Virmani AK, Muller C, Rathi A, et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:584-589.
32. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009;15:6185-6191.
33. Veena MS, Lee G, Keppler D, et al. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer 2008;47:740-754.
34. Yoshida S, Kajitani N, Satsuka A, et al. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol 2008;82:8820-8827.
35. Ren J, He W, Zhang R, et al. RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level. J Huazhong Univ Sci Technolog Med Sci 2009;29:309-312.
36. Guerrero D, Guarch R, Ojer A, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. Int J Cancer 2011;128:2853-2864.
37. Biewenga P, van der Velden J, Mol BW, et al. Prognostic model for survival in patients with early stage cervical cancer. Cancer 2011;117:768-776.
38. Zhao L, Cui Q, Lu Z, et al. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features. Pancreas 2012;41:206-211.
39. Shi J, Zhang G, Yao D, et al. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012;2:116-129.
40. Hiraki M, Kitajima Y, Koga Y, et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol 2011;18: 3013-3019.
41. Lai HC, Lin YW, Chang CC, et al. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 2007;104:629-635.
42. Lof-Ohlin ZM, Sorbe B, Wingren S, et al. Hypermethylation of promoter regions of the APC1A and p16INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients. Int J Oncol 2011;39:683-688.
43. Yang N, Eijsink JJ, Lendvai A, et al. Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers Prev 2009;18: 3000-3007.
44. Choi YL, Kang SY, Shin YK, et al. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 2006;448:331-336.
45. Yageta M, Kuramochi M, Masuda M, et al. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002;62:5129-5133.
46. Dafou D, Grun B, Sinclair J, et al. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia 2010;12:579-589.